U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C7H17NO5.C4H4O4.2Na
Molecular Weight 357.2653
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEGLUMINE SODIUM SUCCINATE

SMILES

[Na+].[Na+].[O-]C(=O)CCC([O-])=O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

InChI

InChIKey=AEKLPNAELPOQBI-RHLRHBBGSA-L
InChI=1S/C7H17NO5.C4H6O4.2Na/c1-8-2-4(10)6(12)7(13)5(11)3-9;5-3(6)1-2-4(7)8;;/h4-13H,2-3H2,1H3;1-2H2,(H,5,6)(H,7,8);;/q;;2*+1/p-2/t4-,5+,6+,7+;;;/m0.../s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C7H17NO5
Molecular Weight 195.2136
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Meglumine (N-methyl-D-glucamine) is a poorly metabolized derivative of sorbitol that has regulatory acceptance as a benign excipient for drug formulation to increase aqueous solubility of lipophilic drugs and improve their absorption. In conjugated form meglumine is used as a contrast agent.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
ISOPAQUE 280

Approved Use

Unknown

Launch Date

1974
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis.
2002-09-06
Cytostatic potential of novel agents that inhibit the regulation of intracellular pH.
2002-07-15
Chemotherapy of canine leishmaniosis.
2002-07-02
Unusual location of cutaneous leishmaniasis on the hallux in a Brazilian patient.
2002-07
Physiologic increases in extracellular sodium salt enhance coronary vasoconstriction and Ca2+ entry.
2002-07
Intrarenal detection of nitric oxide using electron spin resonance spectroscopy in hypertensive lipopolysaccharide-treated rats.
2002-07
A mechanogated nonselective cation channel in proximal tubule that is ATP sensitive.
2002-07
Leishmaniasis in the genital area.
2002-06-06
Evaluation of a rapid immunochromatographic test for serodiagnosis of visceral leishmaniasis.
2002-06
Phospholipase C-mediated signalling is not required for histamine-induced catecholamine secretion from bovine chromaffin cells.
2002-06
Visceral leishmaniasis in paediatrics.
2002-06
Mechanosensitive cation channels in human leukaemia cells: calcium permeation and blocking effect.
2002-05-15
Role of helix 3 in pore formation by the Bacillus thuringiensis insecticidal toxin Cry1Aa.
2002-05-14
The effect of different buffers and amounts of intestinal alkaline phosphatase isoforms on total alkaline phosphatase activity.
2002-05-07
In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
2002-05-02
[Cutaneous leishmaniasis of the lid].
2002-05
Leishmanicidal activity of two canthin-6-one alkaloids, two major constituents of Zanthoxylum chiloperone var. angustifolium.
2002-05
Intracellular pH response to anoxia in acutely dissociated adult rat hippocampal CA1 neurons.
2002-05
Nonselective cation conductance activated by muscarinic and purinergic receptors in rat spiral ganglion neurons.
2002-05
Antimony(V) complex formation with adenine nucleosides in aqueous solution.
2002-04-15
Analysis of lipoproteins by capillary zone electrophoresis in microfluidic devices: assay development and surface roughness measurements.
2002-04-01
Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
2002-04
Characteristics of ATP-induced current through P2X7 receptor in NG108-15 cells: unique antagonist sensitivity and lack of pore formation.
2002-04
Dehydroascorbic acid uptake by coronary artery smooth muscle: effect of intracellular acidification.
2002-03-01
Pediatric visceral leishmaniasis in Albania.
2002-03
An outbreak of cutaneous leishmaniasis among soldiers in Belém, Pará State, Brazil, caused by Leishmania (Viannia) lindenbergi n. sp. A new leishmanial parasite of man in the Amazon region.
2002-03
[Isolated laringeal leishmaniasis and bone marrow culture (reply)].
2002-03
Monovalent cation permeability and Ca(2+) block of the store-operated Ca(2+) current I(CRAC )in rat basophilic leukemia cells.
2002-03
Dual effect of blocking agents on Ca2+-activated Cl(-) currents in rabbit pulmonary artery smooth muscle cells.
2002-02-15
Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial.
2002-02
Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis.
2002-02
PCR detection of specific Leishmania-DNA in patients with periodontal disease.
2002-02
Gender differences in vascular smooth muscle reactivity to increases in extracellular sodium salt.
2002-02
Voltage-dependent cation channels permeable to NH(+)(4), K(+), and Ca(2+) in the symbiosome membrane of the model legume Lotus japonicus.
2002-02
Fluorescence studies of ligand-induced conformational changes of the Na(+)/glucose cotransporter.
2002-01-29
Characterization of the maitotoxin-activated cationic current from human skin fibroblasts.
2002-01-01
Na+-Ca2+ exchange activity in rat skeletal myotubes: effect of lithium ions.
2002-01
Leishmaniasis of the prepuce.
2002-01
Oral leishmaniasis in a HIV-positive patient. Report of a case involving the palate.
2002-01
Visceral leishmaniasis with pericarditis in an HIV-infected patient.
2002
Visceral childhood leishmaniasis in Turkey.
2002
The contributions of plasma membrane Na+-Ca2+-exchange and the Ca2+-ATPase to the regulation of cytosolic calcium ([Ca2+]i) in a clonal pituitary cell line (AtT-20) of mouse corticotropes.
2001-12-28
The traditional and conventional medical treatment of cutaneous leishmaniasis in rural Ecuador.
2001-12
Release of nitric oxide together with carbon-centered radicals from N-nitrosamines by ultraviolet light irradiation.
2001-12
Chemotherapy of cutaneous leishmaniasis: a review.
2001-11
Nitric oxide generation in aqueous solutions of cigarette smoke and approaches to its origin.
2001-11
[Imported cutaneous leishmaniasis caused by Leishmania infantum confirmed with immunoassay].
2001-10
Background osmolyte current involved in cell volume regulation of neuroblastoma x glioma hybrid NG108-15 cells.
2001-09
American cutaneous leishmaniasis as a rare imported disease in Europe: a case report favourably treated with antimonial derivatives.
2001
Splenic granulomatous lesions in immunocompetent pediatric patients with visceral leishmaniasis.
2001
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 10:43:25 GMT 2025
Edited
by admin
on Wed Apr 02 10:43:25 GMT 2025
Record UNII
S6TZ9PZ872
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
REAMBERIN
Preferred Name English
MEGLUMINE SODIUM SUCCINATE
Common Name English
D-GLUCITOL, 1-DEOXY-1-(METHYLAMINO)-, BUTANEDIOATE (SALT), SODIUM SALT
Systematic Name English
N-METHYLGLUCAMINE SUCCINATE SODIUM
Common Name English
D-GLUCITOL, 1-DEOXY-1-(METHYLAMINO)-, BUTANEDIOATE, SODIUM SALT
Systematic Name English
Meglumine sodium succinate [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
157088853
Created by admin on Wed Apr 02 10:43:25 GMT 2025 , Edited by admin on Wed Apr 02 10:43:25 GMT 2025
PRIMARY
CAS
787635-26-1
Created by admin on Wed Apr 02 10:43:25 GMT 2025 , Edited by admin on Wed Apr 02 10:43:25 GMT 2025
NON-SPECIFIC STOICHIOMETRY
SMS_ID
100000181471
Created by admin on Wed Apr 02 10:43:25 GMT 2025 , Edited by admin on Wed Apr 02 10:43:25 GMT 2025
PRIMARY
FDA UNII
S6TZ9PZ872
Created by admin on Wed Apr 02 10:43:25 GMT 2025 , Edited by admin on Wed Apr 02 10:43:25 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY